Loading...
VIMIAN logo

Vimian Group AB (publ)OM:VIMIAN Rapporto sulle azioni

Cap. di mercato SEK 15.9b
Prezzo delle azioni
SEK 30.10
SEK 33.82
11.0% sottovalutato sconto intrinseco
1Y-21.9%
7D5.8%
Valore del portafoglio
​
Vista

Vimian Group AB (publ)

Report azionario OM:VIMIAN

Capitalizzazione di mercato: SEK 15.9b

Vimian Group (VIMIAN) Panoramica del titolo

Vimian Group AB (publ) opera nel settore della salute animale a livello mondiale. Maggiori dettagli

VIMIAN analisi fondamentale
Punteggio fiocco di neve
Valutazione3/6
Crescita futura4/6
Prestazioni passate4/6
Salute finanziaria4/6
Dividendi0/6

Premi

Negoziato a 20.8% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 27.58% all'anno

Gli utili sono cresciuti del 90.7% nell'ultimo anno

Analisi del rischio

Non sono stati rilevati rischi per VIMIAN dai nostri controlli di rischio.

VIMIAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Concorrenti di Vimian Group AB (publ)

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Vimian Group
Prezzi storici delle azioni
Prezzo attuale dell'azioneSEK 30.10
Massimo di 52 settimaneSEK 46.00
Minimo di 52 settimaneSEK 24.18
Beta1.18
Variazione di 1 mese4.95%
Variazione a 3 mesi13.07%
Variazione di 1 anno-21.86%
Variazione a 3 anni-18.65%
Variazione a 5 annin/a
Variazione dall'IPO-62.79%

Notizie e aggiornamenti recenti

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.

Recent updates

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.

VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance

Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.

Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Is Vimian Group (STO:VIMIAN) Using Too Much Debt?

Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?

VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade

Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.

VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative

Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.

VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative

Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook

Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.

VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade

Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.

VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience

Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.

Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)

Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
User avatar

iM3 Acquisition Will Expand Presence In Veterinary Dental Space

Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Rendimenti per gli azionisti

VIMIANSE Medical EquipmentSE Mercato
7D5.8%-2.5%-1.9%
1Y-21.9%-9.8%11.0%

Ritorno vs Industria: VIMIAN ha avuto una performance inferiore rispetto al Swedish Medical Equipment che ha registrato un rendimento -9.8 % nell'ultimo anno.

Rendimento vs Mercato: VIMIAN ha avuto una performance inferiore al mercato Swedish che ha registrato un rendimento 11 % nell'ultimo anno.

Volatilità dei prezzi

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement5.8%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.6%
10% most volatile stocks in SE Market13.1%
10% least volatile stocks in SE Market3.8%

Prezzo delle azioni stabile: VIMIAN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swedish.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di VIMIAN è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
20201,033Alireza Tajbakhshvimian.com

Vimian Group AB (publ) opera nel settore della salute animale a livello mondiale. Opera attraverso i segmenti Specialty Pharma, MedTech, Diagnostics e Veterinary Services. Con il marchio Nextmune, l'azienda offre prodotti diagnostici di proprietà, trattamenti con e senza prescrizione medica per la prevenzione e il trattamento delle patologie croniche degli animali da compagnia; con il marchio Indical Bioscience, soluzioni di immunodiagnostica e molecolare utilizzate dai laboratori per applicazioni veterinarie specifiche, con particolare attenzione ai mercati della salute del bestiame e degli animali da compagnia.

Vimian Group AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Vimian Group con la sua capitalizzazione di mercato?
VIMIAN statistiche fondamentali
Capitalizzazione di mercatoSEK 15.93b
Utili (TTM)SEK 397.92m
Ricavi(TTM)SEK 4.69b
40.0x
Rapporto P/E
3.4x
Rapporto P/S

VIMIAN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
VIMIAN Conto economico (TTM)
Ricavi€433.60m
Costo del fatturato€134.40m
Profitto lordo€299.20m
Altre spese€262.40m
Utili€36.80m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

Jul 17, 2026

Utile per azione (EPS)0.07
Margine lordo69.00%
Margine di profitto netto8.49%
Rapporto debito/patrimonio netto31.5%

Come si è comportato VIMIAN nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/03 03:07
Prezzo dell'azione a fine giornata2026/04/30 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Vimian Group AB (publ) è coperta da 10 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullABG Sundal Collier
Jonathon UnwinBarclays
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB